12 results about "Virus Structural Proteins" patented technology

The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of oncolytic defective virus compositions and methods of in vivo synthesis thereof. The composition includes a first nucleic acid construct encoding a self-amplifying mRNA (sa-mRNA) encoding at least one gene of interest (GOI) or a plurality of GOIs, a second nucleic acid construct encoding an mRNA encoding at least one virus structural protein, and at least one payload delivery system.

The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of oncolytic defective virus compositions and methods of in vivo synthesis thereof. The composition includes a first nucleic acid construct encoding a self-amplifying mRNA (sa-mRNA) encoding at least one gene of interest (GOI) or a plurality of GOIs, a second nucleic acid construct encoding an mRNA encoding at least one virus structural protein, and at least one payload delivery system.

The invention belongs to the field of gene engineering, and particularly relates to application of chikungunya virus structural protein in improvement of pseudovirus stability, a construction method of the chikungunya virus structural protein and vaccines, antibody evaluation and in-vivo gene therapy products. The method comprises the following steps: constructing a human codon optimized Asian strain CHIKV-E3 + E2 + 6K + E1 structural protein eukaryotic vector, and designing two types of binder expression plasmids of targeted T cells; the vector, a psPAX2 helper plasmid and a lentivirus target vector containing an SFFV promoter and a ZsGreen reporter gene (or a CAR therapeutic gene) are co-transformed into a 293T cell, and the lentivirus is prepared through culture, filtration and centrifugation. The lentivirus can efficiently infect Jurkat cells and activate human T cells, obviously reduces the infection efficiency on 293T cells so as to reduce the off-target effect, has excellent stability in human serum, and provides a safe and efficient gene delivery tool for in-vivo CAR-T therapy.

The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of oncolytic defective virus compositions and methods of in vivo synthesis thereof. The composition includes a first nucleic acid construct encoding a self-amplifying mRNA (sa-mRNA) encoding at least one gene of interest (GOI) or a plurality of GOIs, a second nucleic acid construct encoding an mRNA encoding at least one virus structural protein, and at least one payload delivery system.

The invention discloses a method for purifying foot-and-mouth disease virus-like particles expressed by pichia pastoris by adopting an affinity chromatography mode. The method comprises the following steps: expressing plasmids cloned with foot-and-mouth disease virus structural protein VP0, VP3 and VP1-GHH genes, plasmids cloned with foot-and-mouth disease virus structural protein VP0, VP3-CH and VP1 genes or plasmids cloned with foot-and-mouth disease virus structural protein VP0, VP3 and VP1-CH genes through pichia pastoris to obtain foot-and-mouth disease virus-like particles, and then purifying by adopting affinity chromatography. The inventor finds a place where a His6 affinity label can be inserted by exploring the structure of the foot-and-mouth disease virus-like particle, so that the aim of purifying the virus-like particle by utilizing an affinity chromatography method is fulfilled. The establishment of the method provides a new technical means for research on preparation of foot-and-mouth disease virus-like particles by a pichia pastoris expression system and purification and industrial production of the virus-like particles.

The invention relates to the technical field of biology, in particular to a porcine reproductive and respiratory syndrome virus subunit vaccine. Through bioinformatics analysis and experimental verification, the antigen protein with excellent immunogenicity is obtained through screening, and the amino acid sequence of the antigen protein is shown as SEQ ID NO: 1. The subunit vaccine constructed on the basis of the protein can effectively induce mice to generate high-level neutralizing antibodies, the effect of the subunit vaccine is remarkably better than that of commercial control vaccines, the mice can be stimulated to generate strong humoral immunity and cellular immunity at the same time, and the induced immune response type is mainly Th2 type. Further research shows that the antigen protein and the virus structural protein E + M are combined for immunization, and the immune effect of the structural protein can be remarkably enhanced. The subunit vaccine developed by the invention provides a new thought for research and development of novel vaccines for resisting PRRSV and other viral diseases.

The invention belongs to the technical field of veterinary biological products, and particularly relates to a CATHAY topological truncated foot-and-mouth disease virus-like particle antigen and application thereof. Compared with the precursor protein P1 of the wild type foot-and-mouth disease virus structural protein, the precursor protein P1 of the CATHAY topological truncated foot-and-mouth disease virus structural protein has the advantage that 10-40 amino acids are truncated at the N end. While the relatively strong capability of inducing an organism to generate an antibody of the full-length wild capsid protein is reserved, the protein has the characteristics of high expression quantity, easiness in purification, high uniformity, high stability and the like.

The invention belongs to the technical field of veterinary biological products, and particularly relates to an O-type truncated foot-and-mouth disease virus-like particle antigen and application thereof. Compared with a wild type foot-and-mouth disease virus structural protein precursor protein P1, the O-type truncated foot-and-mouth disease virus structural protein precursor protein P1 has the advantage that 10-40 amino acids are truncated at the N end of the O-type truncated foot-and-mouth disease virus structural protein precursor protein P1. While the relatively strong capability of inducing an organism to generate an antibody of the full-length wild capsid protein is reserved, the protein has the characteristics of high expression quantity, easiness in purification, high uniformity, high stability and the like.

The invention belongs to the technical field of veterinary biological products, and particularly relates to an A-type truncated foot-and-mouth disease virus-like particle antigen and application thereof. Compared with a wild type foot-and-mouth disease virus structural protein precursor protein P1, the N end of the A type truncated foot-and-mouth disease virus structural protein precursor protein P1 is truncated by 10-40 amino acids. While the relatively strong capability of inducing an organism to generate an antibody of the full-length wild capsid protein is reserved, the protein has the characteristics of high expression quantity, easiness in purification, high uniformity, high stability and the like.

The present application relates to the technical field of virology, more particularly to O-type foot-and-mouth disease virus-like particle antigen and its preparation method and application. The O-type foot-and-mouth disease virus structural protein is constructed, and the recombinant expression vector comprises a Sumo-VP1 sequence, a Sumo-VP3 sequence, a Sumo-VP0 sequence and a chaperone sequence; the recombinant expression vector is transformed into a genetically engineered bacterium, and Sumo-VP1 protein, Sumo-VP3 protein, Sumo-VP0 protein and chaperone protein are expressed; the initial extraction solution is obtained by crushing; the purified extraction solution is obtained by purification; the self-assembled O-type foot-and-mouth disease virus-like particle antigen is obtained by enzyme cutting and removal of Sumo enzyme. The present application improves the soluble expression proportion and overall expression amount of the target protein in the supernatant by optimizing the construction mode and transformation strategy of the foot-and-mouth disease structural protein, and overcomes the technical bottleneck that the supernatant expression amount of the existing E. coli expression system is low and the inclusion body is prone to be formed.

The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of oncolytic defective virus compositions and methods of in vivo synthesis thereof. The composition includes a first nucleic acid construct encoding a self-amplifying mRNA (sa-mRNA) encoding at least one gene of interest (GOI) or a plurality of GOIs, a second nucleic acid construct encoding an mRNA encoding at least one virus structural protein, and at least one payload delivery system.

The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of oncolytic defective virus compositions and methods of in vivo synthesis thereof. The composition includes a first nucleic acid construct encoding a self-amplifying mRNA (sa-mRNA) encoding at least one gene of interest (GOI) or a plurality of GOIs, a second nucleic acid construct encoding an mRNA encoding at least one virus structural protein, and at least one payload delivery system.